Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MFIC hit new 52 week hi yesterday and profit taking today makes it a good buy esp since Taglich raised target to $2.80.
By: funddumbmental
12 Dec 2006, 09:20 AM EST
Msg. 9436 of 9452
Jump to msg. #
Taglich raises target to $2.80!
He really had no choice at the stock met his price target - early!
Still a very lowball number vs other firms that John follows like the money losing low sales Daxor (DEX) with a $25 target.
I predict John will be raising his MFIC price target again in January!
http://www.taglichbrothers.com/equityuniverse/companies/mficcorp/mficcorp.asp
I would appreciate anyone telling me what this PR means,lol?
MOSCOW -- (MARKET WIRE) -- December 12, 2006 -- North-West Oil Group (PINKSHEETS: NWOG) (FRANKFURT: CXIA) signed the confidential agreement with major shareholders of one of the Russian oil company and according to the results of the investigated materials prepared by international experts specializing on an estimation of assets was offered objective cost of the asset in volume of $ 25 million for proposed deposit. The company expects to receive the answer from the major shareholders of the oil company concerning a suggested price within two weeks. The general proved stocks of the offered deposit according to category C1- 9,256,400 barrels. Development of the deposit began in 2003, extraction and realization in 2004. The oil recovery is carried out from two drillings. In case of purchasing the asset total reserves of the North-West Oil Group company by category C1 will reach - 46,006,000 barrels
I just bought more AURC at .16 even though Parkin is still involved with the company. Hopefully he has learned to use "standard" time rather than "Parkin" time.
I was immediately filled at .16
Calypte Announces First Russian Sales Order
Tuesday December 12, 8:30 am ET
LAKE OSWEGO, Ore., Dec. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received the initial order from its distributor in Russia, Ordynka Investments Limited, for 25,000 of its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid tests for the OTC market in the Russian Federation. This product, designed for use in non-clinical settings, permits significantly greater access to HIV testing.
Mr. Vladimir Saveliev, Managing Director of Ordynka Investments Limited, stated "We are happy to be working with Calypte in the hope to be able to help Russia in its fight against the prevention of the spread of the fast growing HIV/AIDS epidemic and this initial order of 25,000 test kits should help the cause. In addition to being safe and painless, oral fluid sampling is very efficient and thereby facilitates high-throughput testing in settings such as the military, prisons, schools and universities. Additionally, oral fluid sampling facilitates testing in many settings, such as outreach or prevalence surveys in remote locations, where drawing blood is difficult or even impossible."
Mr. Saveliev continued, "We intend to deliver no less than 500,000 tests to the Russian Federation over the next 12 months and are confident that the need for these products can be greater than this."
One of the fundamental aspects of HIV intervention is the identification of infected individuals so that they may be counseled and referred to therapy. Although a portion of HIV infections may be identified through a variety of mandated, institutionalized testing programs, the identification of infections in the general population relies largely on the public's voluntary participation in testing programs.
Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "While HIV testing in Russia is already extensive, our recently approved AwareTM HIV-1/2 OMT (oral fluid) rapid test overcomes several barriers to testing as it is a non-invasive test. As such, we believe it will form the basis for a quality post-testing counseling system - for prevention as well as treatment."
Mr. Gale continued, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose principals come from this region, and we are optimistic that their contacts in the region will maximize our ability to serve the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic."
Calypte Announces First Russian Sales Order
Tuesday December 12, 8:30 am ET
LAKE OSWEGO, Ore., Dec. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received the initial order from its distributor in Russia, Ordynka Investments Limited, for 25,000 of its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid tests for the OTC market in the Russian Federation. This product, designed for use in non-clinical settings, permits significantly greater access to HIV testing.
Mr. Vladimir Saveliev, Managing Director of Ordynka Investments Limited, stated "We are happy to be working with Calypte in the hope to be able to help Russia in its fight against the prevention of the spread of the fast growing HIV/AIDS epidemic and this initial order of 25,000 test kits should help the cause. In addition to being safe and painless, oral fluid sampling is very efficient and thereby facilitates high-throughput testing in settings such as the military, prisons, schools and universities. Additionally, oral fluid sampling facilitates testing in many settings, such as outreach or prevalence surveys in remote locations, where drawing blood is difficult or even impossible."
Mr. Saveliev continued, "We intend to deliver no less than 500,000 tests to the Russian Federation over the next 12 months and are confident that the need for these products can be greater than this."
One of the fundamental aspects of HIV intervention is the identification of infected individuals so that they may be counseled and referred to therapy. Although a portion of HIV infections may be identified through a variety of mandated, institutionalized testing programs, the identification of infections in the general population relies largely on the public's voluntary participation in testing programs.
Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "While HIV testing in Russia is already extensive, our recently approved AwareTM HIV-1/2 OMT (oral fluid) rapid test overcomes several barriers to testing as it is a non-invasive test. As such, we believe it will form the basis for a quality post-testing counseling system - for prevention as well as treatment."
Mr. Gale continued, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose principals come from this region, and we are optimistic that their contacts in the region will maximize our ability to serve the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic."
MFIC hits new 52 week high today-$2.05
The President of the North-West Oil Group, Mr. Ernest Malyshev, Announces Telephone Conference With Investors
The president of the North-West Oil Group (PINKSHEETS: NWOG) (FRANKFURT: CXIA), Mr. Ernest Malyshev, announces that on Thursday, December 14, 2006, a telephone conference will take place with the investors from 18.00 till 20.00 Moscow time. In connection with an expected big stream of phone calls, each investor will be provided one minute for the conversation and the line will disconnected automatically, in purpose to accept as many possible phone calls from the investors. Phone number for connection is +7 (495) 621 11 15. In relationship with the above- stated information we kindly ask the investors to formulate their questions particularly and briefly.
About North-West Oil Group (formerly Nord Oil International)
North-West Oil Group is a non-reporting, publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pinksheets market as well as on the Frankfurt Exchange under symbol CXIA. The company presently produces over 120,000 Metric Tons of crude oil yearly.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Source: Market Wire (December 11, 2006 - 1:45 PM EST)
News by QuoteMedia
www.quotemedia.com
Fish-ask him if he is the same "fisty" of many aliases who was thrown off the RB board for vulgarity,mult.aliases, etc.
>You have a very negative history in regards to this stock..I questions your motives..<
Yeah, I tos,ed you for your vulgar/suggestive alias. Who would believe someone with a name like yours???
Company On Target With Its Planned Studies Of H1N1, H5N1, And Rabies, To Be Independently Monitored, Scheduled For The First Quarter 2007
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc., (Pink Sheets: NNVC - News)
Dr. Anil Diwan, Company President and Chairman, was selected to speak at "Advances in Nanotechnology Conference - Biomedical Applications, 2006" held at the Moffitt Cancer Center in Tampa, FL, on Dec. 8th. He outlined the significant advantages of the nanoviricides(tm) approach, and the underlying nanomicelle(tm) polymeric micelle technologies, over currently existing technologies.
Dr. Diwan also made it clear that only the nanoviricides technology offers a solution to potential pandemic-causing attacks by novel pathogens, whether they occur as a result of bioterrorism or natural events. This is of major interest to Biodefense professionals. In addition he explained how the Company's technologies can be of significant assistance to the bio-emergency preparedness efforts that are occurring world-wide.
"The leadership position of NanoViricides in the field of NanoMedicine is well recognized," said Eugene Seymour, MD, CEO, about this presentation.
Previously, Dr. Seymour presented the Company's work at the 3rd International Bird Flu Conference in Geneva, Switzerland on November 15th. He stressed the fact to the International Health audience assembled at the Conference that the Company's scientists were working as fast as possible on both avian and seasonal influenza drug developments, "now that it is clear that the nanoviricides are the most efficacious drugs against all influenzas."
NanoViricides also announced that it is on target with its planned studies of H1N1 (common influenza), H5N1 (bird flu), and rabies scheduled for the first quarter 2007, as explained in the Company's filed SEC Form 10SB. The success of these animal studies, to be independently monitored by Vietnamese government scientists, would be expected to result in the creation of drugs with "blockbuster" potential. However even more important to our shareholders and the general public, this will further validate the nanoviricides(tm) technology and hasten the development of drugs by NanoViricides with even larger market sizes such as Hepatitis C (HCV) and HIV.
Company On Target With Its Planned Studies Of H1N1, H5N1, And Rabies, To Be Independently Monitored, Scheduled For The First Quarter 2007
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc., (Pink Sheets: NNVC - News)
Dr. Anil Diwan, Company President and Chairman, was selected to speak at "Advances in Nanotechnology Conference - Biomedical Applications, 2006" held at the Moffitt Cancer Center in Tampa, FL, on Dec. 8th. He outlined the significant advantages of the nanoviricides(tm) approach, and the underlying nanomicelle(tm) polymeric micelle technologies, over currently existing technologies.
Dr. Diwan also made it clear that only the nanoviricides technology offers a solution to potential pandemic-causing attacks by novel pathogens, whether they occur as a result of bioterrorism or natural events. This is of major interest to Biodefense professionals. In addition he explained how the Company's technologies can be of significant assistance to the bio-emergency preparedness efforts that are occurring world-wide.
"The leadership position of NanoViricides in the field of NanoMedicine is well recognized," said Eugene Seymour, MD, CEO, about this presentation.
Previously, Dr. Seymour presented the Company's work at the 3rd International Bird Flu Conference in Geneva, Switzerland on November 15th. He stressed the fact to the International Health audience assembled at the Conference that the Company's scientists were working as fast as possible on both avian and seasonal influenza drug developments, "now that it is clear that the nanoviricides are the most efficacious drugs against all influenzas."
NanoViricides also announced that it is on target with its planned studies of H1N1 (common influenza), H5N1 (bird flu), and rabies scheduled for the first quarter 2007, as explained in the Company's filed SEC Form 10SB. The success of these animal studies, to be independently monitored by Vietnamese government scientists, would be expected to result in the creation of drugs with "blockbuster" potential. However even more important to our shareholders and the general public, this will further validate the nanoviricides(tm) technology and hasten the development of drugs by NanoViricides with even larger market sizes such as Hepatitis C (HCV) and HIV.
Great post brent and I dont blame anyone but myself for my paper losses. I did sell my .02 shares for .20 but my greed made me buy more SLJB later even though I had some doubts about the story sounding too good to be true.
One of these days I will learn to take ALL of my profits,lol.
Axiom, actually he is only here out of the goodness of his heart to save us from ourselves. Is not that great from someone who owns no Calypte stock?
Signed by Me
Why was he banned?
Yeah, some of us like to look at both sides!
North-West Oil Group Received USD 15.5 Million From Hungarian Oil and Gas (MOL) Company for Sale of Surgutsky 7
5:52a ET December 7, 2006 (Market Wire)
North-West Oil Group (PINKSHEETS: NWOG) (FRANKFURT: CXIA) signed a sales agreement with the Hungarian Oil and Gas (MOL) company on the purchase of 100% of the NWOG-MOL project which develops a site Surgutsky-7 for USD 15.5 million and completed transaction. It is the first Russian asset of the MOL for investigation of the deposit which purchased because of the provided opportunity from North-West Oil Group. The funds shall be used for an immediate acquisition of oil reserves which will enhance the assets of the company and in particular a part of received funds will be directed on purchase of the site Lugovskoe declared to an auction on December 12, 2006 in which the company takes part. The Lugovskoe is located in Saratov region with plottage of 11.6 km2 and driven back for investigation and recovery of oil and gas. The reserves of the Lugovskoe according to category C1 are: oil -- 2,547,700 barrels and free gas 13 million m3. In case purchasing the deposit company will have the established license for investigation and extraction during 20 years and in January or February 2007 extraction can be carried out.
About North-West Oil Group (formerly Nord Oil International)
North-West Oil Group is a non-reporting, publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pinksheets market as well as on the Frankfurt Exchange under symbol CXIA. The company presently produces over 120,000 Metric Tons of crude oil yearly.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact: Maria Romanova North-West Oil Group Tel: +7 495 621 1115 E-Mail: maria@szng.ru Web: www.szng.ru
SOURCE: North-West Oil Group
mailto:maria@szng.ru http://www.szng.ru
Well that should give the board some relief from hundreds of useless posts today. Now, if we could just get more in jail?
Do what???
Airys418, thanks for all the good DD you, H.O.G. and several others do for this board but you mods need to ban many posters who clog with useless posts. Those of us who cant be here 24/7 miss many good posts because of the "garbage". For instance, a poster who was banned, and allowed back on, posted over 100 times in one day.
As another poster said " this board has turned into a chat room for teenager types who have nothing better to do".
Thanks -looks better today.
34/54 re my previous post yesterday. Do you know why the big decrease in NWOG (yesterday).
Brent, anyone; was out all day and got surprised with NWOG pps esp after I bought more yesterday at .079 (I think). Saw where Parkin is out and would have expected that to be good news. Is it just tax selling?
With all we have gone through with Parkin I would expect his leaving would help both stocks.
I was busy all day and turned on the puter at 3:30. Was surprised to see NWOG at .079 ask and placed small order. It was filled around 3:57.
Did not pull the trigger on AURC or NWOG. Was waiting for AURC to retrace a little :), and for NWOG to settle down :( some.
Unigene Engages University Clinicians to Advise on Bone Growth Program Company Also Acquires License to Bone Growth Patent Applications
Thursday Nov 30 2006 08:30:24 EST
FAIRFIELD, N.J., Nov 30, 2006 (BUSINESS WIRE) --
Unigene Laboratories, Inc. (OTCBB: UGNE) has engaged two leading clinicians as consultants to assist in the development and testing relating to the Site-Directed Bone Growth program currently being conducted by the company in collaboration with investigators from Yale University Medical School.
Unigene scientists, in collaboration with Dr. Agnes Vignery at Yale, co-invented the Site-Directed Bone Growth technology, which involves the use of a simple, minimally invasive outpatient procedure in conjunction with the administration of an anabolic drug that has been shown in animals to facilitate and accelerate natural bone growth at precisely targeted locations. Possible applications of this technology include strengthening of weakened or damaged bones due to osteoporosis or fractures, the treatment of chronic back pain, the prevention of hip fractures and the improvement of bone healing.
The new consultants are leading medical professionals from the Johns Hopkins University School of Medicine:
Dr. Donlin Long, a Distinguished Senior Professor of Neurosurgery at the Johns Hopkins University School of Medicine was also the Neurosurgeon-in-Chief of the Johns Hopkins Hospital and Director of the Department of Neurosurgery at that institution from 1973 to 2000. He has authored more than 200 papers and authored or contributed to over 100 books in bone and related areas. He is actively involved in neurosurgery practice and has a major interest in the origins of spinal pain and the outcomes of treatment of spinal diseases. He is also one of the founders of the International Association for The Study of Pain.
Dr. Kieran Murphy is a Director of Interventional Neuroradiology and Associate Professor of Radiology, Neurology and Neurological Surgery at the Johns Hopkins University School of Medicine. Dr. Murphy is a pioneer in the field of image guided/minimally invasive spine intervention, and the inventor of devices for vertebral stabilization (the Murphy needles) that have become the industry standard worldwide. He has authored more than 100 peer-reviewed publications. His research focus is in the area of image-guided spine intervention with a particular interest in prophylactic spine, hip, and wrist augmentation to reduce inevitable osteoporotic fractures in high-risk patients.
"We are understandably excited to add these outstanding medical experts to our development team for the Site-Directed Bone Growth program," stated Dr. Warren Levy, President and CEO of Unigene. "In collaboration with our colleagues at Yale University Medical School, we plan to explore the many potential applications of this novel technology, including intervention to prevent bone failure and relief of spinal pain by rebuilding bone naturally rather than replacing it with other foreign material."
In conjunction with this program, Unigene has licensed three of Dr. Murphy's patent applications to strengthen its intellectual property portfolio. The patent applications involve the use of specialized equipment and procedures to deliver substances that promote bone growth or strengthen existing bone.
"These novel delivery approaches and combinations should expand our patent protection and complement the Site-Directed Bone Growth technology in ways that may enable and facilitate additional commercialization options," Dr. Levy added.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.
SOURCE: Unigene Laboratories, Inc.
The Investor Relations Group For Unigene
Investors:
Damian McIntosh/Dian Griesel, Ph.D., 212-825-3210
Or
Media:
Janet Vasquez, 212-825-3210
Welcome aboard brent and good luck.
34/54-"hopefully", lol.
Putin Poisons another?
--------------------------------------------------------------------------------
Ex-Russian PM possibly poisoned
Illness follows fatal poisoning of former KGB spy Litvinenko
The Associated Press
Updated: 11:35 a.m. ET Nov 30, 2006
MOSCOW - Doctors treating former Russian Prime Minister Yegor Gaidar, who is ill, believe he was poisoned, an aide said Thursday.
"Doctors don't see a natural reason for the poisoning and they have not been able to detect any natural substance known to them" in Gaidar's body, spokesman Valery Natarov said. "So obviously we're talking about poisoning (and) it was not natural poisoning."
Gaidar, 50, one of the leaders of a liberal opposition party who served briefly as prime minister in the 1990s under President Boris Yeltsin, began vomiting and fainted during a conference in Ireland on Friday, and was rushed into intensive care at a hospital.
Gaidar's illness follows the poisoning of former KGB spy Alexander Litvinenko, who died in London just one day before Gaidar fell ill. Another former KGB spy who met with Litvinenko on the day he was allegedly poisoned, Andrei Lugovoy, served as Gaidar's bodyguard at one point.
Anatoly Chubais, a top Yeltsin-era government official and now head of the national electricity monopoly, said Wednesday that he suspected a link between Gaidar's illness, Litvinenko's death and last month's murder of investigative reporter Anna Politkovskaya.
Natarov said Gaidar was feeling better Thursday. "His condition is stable and improving. Doctors say there is no threat to his life at the moment."
© 2006 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
URL: http://www.msnbc.msn.com/id/15969441/
Sorry for your loss brent. I am still holding my .07 shares for an all or nothing gamble. As I said earlier, I do not play poker and pennies are my Vegas. I let greed rule my better judgement when I sold my .02 shares for .20 and held the remaining. Guess I will never learn to take ALL my profits,lol.
Whats up with NWOG-from oil to liquor???
http://www.szng.ru/nov_e.html
Thanks to those 4 who replied to my AURC vs NWOG question. Much appreciated. I am leaning toward AURC as I am a bit overloaded with NWOG but need to take a chance and av down with the pps being so low. Of course NWOG could go even lower :).
Ok folks, I have a little extra money to gamble with tomorrow if the price is right. Which should I buy, NWOG or AURC :)? TIA.
So, do you think Parkin would let me swap 2 of my NWOG shares for 1 of AURC :)?
brent, you beat me to it so I will just place it on BBPenny board. Hate to not use it,lol.
SLJB -- Synergy Between Former CEO and New Team Is Formidable Against Criticisms
Wednesday November 29, 9:15 am ET
WINDSOR, ON--(MARKET WIRE)--Nov 29, 2006 -- Sulja Bros. Building Supplies Ltd. (Other OTC:SLJB.PK - News) today is responding to recent events and shareholder concerns. What follows is a statement from the CEO of SLJB, Mr. Steve Sulja and the current management team now set in place to carry on with the vision of the corporation:
ADVERTISEMENT
As previously set forth for public scrutiny, this company is currently forwarding all relevant documents and authorizations for streamlined distribution of pertinent public information to our accountants and attorneys, who will serve as the sole source of information deemed necessary and completely accurate for the public. The Officers and Directors of SLJB want to express their steadfast alliance with the vision and goals of its former CEO and vow to continue in the same light to achieve these objectives in the near future and in the long-run of our operations. Basically, SLJB is aimed still toward new levels of shareholder value and a presence on broader, more prominent exchanges, goals directly relayed from former CEO Petar Vucicevich and taken on as both solid business objectives and as support for the former company leader.
SLJB Management also re-stated that the current onslaught of negative press and its deleterious effects on every aspect of our day-to-day business and, we believe, the injurious downturn on our current share-price is nothing more than pointed sensationalism and an unprovoked tirade serving none but the names of those who would set them forth.
As ever, Petar Vucicevich has ensured the Company that he stands behind SLJB to lend support and guidance for the new team and the Company. His purpose is to promote a smooth transition for the newly inundated management team and to ensure the continued success of the Company, both publicly and internally.
The Company believes that in five short months, an operation has been built that anyone would be proud of, something for our children to know that our team helped to build, and no one here feels at all different, despite the poorly organized drivel of envious onlookers. These onlookers will become even more diffused as the public observes how stringently the Company adheres to upcoming stricter guidelines and compliance issues set forth on the Pink Sheets and larger exchanges in the near future. We will exceed the minimum requirements of these regulations.
In conclusion, the Company announced that it has secured a position at a globally renowned exposition, and to date they are in fact the only North American delegate attending: Project Lebanon 2007 will be held 2/27-3/3 2007 at the Beirut International Exhibition and Leisure Center. This expo represents a market that expects to exceed $3 billion over the next three years. SLJB has positioned itself to garner as much of that market share as is possible. The expo coincides with the Company's completion of all of the service requirements and licensing procedures to open an office in the country operating as SLJB and subsequent offices in the region that will also conduct business under the SLJB title, a move that will make transparent the true ownership and management of the Company's operations overseas.
This may contain forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Forward-looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions: "may," "could," "should" or "might occur." Such forward-looking statements involve certain risks and uncertainties. The actual result may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
Contact:
--------------------------------------------------------------------------------
Source: Sulja Bros. Building Supplies Ltd.
Biophan Makes Two Scientific Presentations at Radiological Society of North America (RSNA) Back
via COMTEX
Nov 28, 2006 6:00:00 AM
ROCHESTER, N.Y., Nov 28, 2006 (BUSINESS WIRE) --
Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, will make two presentations this week at the Radiological Society of North America (RSNA) in Chicago, Illinois, related to new information on MRI safety of pacemakers and similar devices and MRI safety testing procedures.
In the first presentation, entitled "Assessment of MRI Induced Heating of Cardiac Pacing Leads: Relevance to Target Patient Populations," Biophan will present data showing the effectiveness of one of its solutions in reducing the heating of pacemaker leads in an MRI environment, even in the worst case conditions that a patient may encounter.
The presentation also shows the effect of the lead's position in the MRI tube, which can be affected by either how the lead is physically placed in the patient or the location of the patient within the tube. The closer the lead is to the wall of the MRI machine, the greater the heating effect. Biophan's technical solution, a tiny integrated circuit placed in the electrode of the lead, was effective in reducing the heating regardless of the location within the MRI tube.
The second presentation was accepted as a Hot Topic submission, and is entitled "MR Scanner Transmit Gain as an Indicator for Lead Heating." In this presentation, Biophan will provide new data related to MRI safety testing protocols. Biophan's experiments indicate that a setting associated with the MRI machine called transmit gain, which is not currently controlled in most reported MRI safety and heating test results, is an important control variable and a critical indicator when performing MRI lead heating experiments. Not controlling this variable can account for wide variations in reports of heating by many researchers.
Michael Weiner, CEO of Biophan Technologies, commented on the significance of these findings. "These two presentations demonstrate the effectiveness of Biophan's solutions for reducing MRI induced heating in pacemaker leads and Biophan's leadership role in developing appropriate testing procedures related to MRI safety of medical devices.
"These testing procedures will be critical to defining the path for FDA approval of MRI conditionally safe medical devices, including those which will incorporate our technologies. Defining appropriate control variables and solutions that can perform in worst case, clinically relevant scenarios is essential to making medical devices safe for use with MRI."
Both presentations can be viewed at http://www.biophan.com/RSNApresentations2006.
About Biophan